Medix Biochemica Is A Finnish Biotechnology Company Founded In 1985. It Specializes In Developing, Producing, And Supplying High-quality Raw Materials And Diagnostic Tests For The In Vitro Diagnostics (IVD) Industry. The Company Offers A Diverse Range Of Products, Including Native And Recombinant Antibodies, Antigens, Molecular Diagnostic Reagents, Biospecimen Materials, And Enzymes, Catering To Various Clinical Areas Worldwide. The Company Has Expanded Its Capabilities Through Strategic Acquisitions, Enhancing Its Portfolio With Products For Inflammation, Oncology, And Infectious Disease Testing. Medix Biochemica Serves Multiple Clinical Segments, Such As Anemia, Autoimmunity, Cardiac Health, And Covid-19 Testing Solutions. With A Focus On Customer Needs, The Company Provides Tailored Contract Services, Including Antibody Development And Molecular Diagnostics, Ensuring Reliable Delivery And Quality For IVD Manufacturers. Medix Biochemica Is Recognized For Its Scientific Expertise And Commitment To Innovation In Diagnostic Test Development.